Betaine anhydrous in homocystinuria: results from the RoCH registry

Archive ouverte

Valayannopoulos, V. | Schiff, M. | Guffon, N. | Nadjar, Y. | Garcia-Cazorla, A. | Martinez-Pardo Casanova, M. | Cano, A. | Couce, M. L. | Dalmau, J. | Pena-Quintana, L. | Rigalleau, Vincent | Touati, G. | Aldamiz-Echevarria, L. | Cathebras, P. | Eyer, D. | Brunet, D. | Damaj, L. | Dobbelaere, D. | Gay, C. | Hieronimus, S. | Levrat, V. | Maillot, F.

Edité par CCSD ; BioMed Central -

International audience. BACKGROUND: The Registry of Adult and Paediatric Patients Treated with Cystadane(R) - Homocystinuria (RoCH) is a non-interventional, observational, multi-centre, post-authorization safety study that aimed to identify safety of betaine anhydrous (Cystadane(R)) in the treatment of patients with inborn errors of homocysteine metabolism (homocystinuria) in order to minimise the treatment associated risks and establish better knowledge on its clinical use. The registry included patients of all ages with homocystinuria who were treated with betaine anhydrous in conjunction with other therapies. Clinical data were collected retrospectively from 2007 to 2013, then prospectively up to February 2014. All adverse events (AEs) reported during the study were recorded. The clinical and biological status of patients was monitored at least once a year.RESULTS: A total of 125 patients with homocystinuria (adults [> 18 years]: 50; paediatric [

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion